Immune checkpoint inhibitor using in cases with gestational trophoblastic diseases.
Semra PaydaşPublished in: Medical oncology (Northwood, London, England) (2023)
Gestational trophoblastic neoplasias (GTNs) are chemosensitive disorders with very high cure rates. However, individuals with chemoresistant diseases pass away as a result of their illness, necessitating the use of innovative medications. Immune checkpoint inhibitors (ICIs) are a critical component of the strategy for the management of drug-resistant GTD due to the high rate of PD-1 expression and the paternal genetic inheritance in GTNs. Immunotherapy is mentioned as a potential therapeutic approach for chemotherapy-resistant GTD in the most recent worldwide recommendations. However, multicenter worldwide collaborative studies are required to give additional evidence to detect and identify prognostic markers due to the rarity of GTDs and the dearth of data in the literature.
Keyphrases
- drug resistant
- weight gain
- multidrug resistant
- pregnant women
- acinetobacter baumannii
- birth weight
- poor prognosis
- systematic review
- body mass index
- pregnancy outcomes
- mitochondrial dna
- copy number
- genome wide
- clinical practice
- quality improvement
- gene expression
- squamous cell carcinoma
- cross sectional
- radiation therapy
- binding protein
- dna methylation
- gestational age
- physical activity
- case control
- deep learning
- preterm birth